CLAIMS

What is claimed is:

1. Use of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of moderate to severe chronic hand eczema in a subject, wherein a therapeutically effective amount of the medicament is to be administered to said subject in need thereof.

2. The use of claim 1, wherein the therapeutically effective amount is selected from the group consisting of 50, 100 or 200 mg.

3. The use of claim 2, wherein the therapeutically effective amount is 50 mg.

4. The use of claim 2, wherein the therapeutically effective amount is 100 mg.

5. The use of claim 2, wherein the therapeutically effective amount is 200 mg.

6. The use of any of claims 1 to 5, wherein the therapeutically effective amount is to be administered QD.

7. The use of any of claims 1 to 6, wherein the N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide, or a pharmaceutically acceptable salt thereof is to be administered to said subject for up to 16 weeks.

8. The use of any of claims 1 to 7, wherein the N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide, or a pharmaceutically acceptable salt thereof is to be administered to said subject for up to 52 weeks.

9. The use of any of claims 1 to 8, wherein whereby said subject achieves an Investigator Global Assessment (IGA) response score of 0-1 and ≥2 points reduction in score from baseline.

10. The use of claim 9, wherein said subject maintains said IGA response.

11. The use of any of claims 1 to 9, whereby said subject achieves an IGA response score of 0-1 and ≥2 points reduction in score from baseline by Week 16.

12. The use of any of claims 1 to 11, whereby said subject achieves an improvement in Total Lesion Severity Score (TLSS) of at least about 50 to about 70% reduction from baseline TLSS by Week 16.

13. The use of any of claims 1 to 12, whereby said subject achieves a response of at least a 4-point improvement on Worst Itch Numerical Rating Scale (Worst Itch NRS4) by Week 16.

14. The use of any of claims 1 to 13, wherein said subject maintains said improvement in the Worst Itch NRS4 score.

15. The use of any of claims 1 to 14, whereby said subject achieves at least a 20 percent improvement in the Work Productivity and Activity Impairment Questionnaire (WPAI-CHE) Scale by Week 16.

16. The use of any of claim 15, wherein said subject maintains the improvement in the WPAI-CHE score.

17. The use of any of claims 1 to 16, whereby flare as measured by IGA score is maintained at less than or equal to 3.

18. The use of any of claims 1 to 17, wherein the improvement in response is within 14 days.

19. The use of any of claims 1 to 18, further comprising a co-administration ofa topical agent selected from the group consisting of a crisaborole, corticosteroid, a calcineurin inhibitor, pimecrolimus and tacrolimus.

20. The use of claim 19, wherein the topical co-administration is by means of an ointment or cream.